deltatrials
Completed PHASE1 NCT03309111

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma

Sponsor: Glenmark Pharmaceuticals S.A.

Conditions Relapsed/Refractory Multiple Myeloma
Interventions ISB 1342
Updated 21 times since 2017 Last updated: Jun 12, 2024 Started: Oct 25, 2017 Primary completion: Dec 15, 2023 Completion: Dec 15, 2023

This PHASE1 trial investigates Relapsed/Refractory Multiple Myeloma and is currently completed. Glenmark Pharmaceuticals S.A. leads this study, which shows 21 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

    Status: Unknown Status → Completed

  4. Jun 2024 — Jul 2024 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  5. Jun 2022 — Jun 2024 [monthly]

    Recruiting PHASE1

▶ Show 16 earlier versions

  1. Sep 2021 — Jun 2022 [monthly]

    Recruiting PHASE1

    Phase: PHASE1_PHASE2 → PHASE1

  2. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Feb 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  5. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE1

  6. Aug 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  7. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  8. Jan 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  9. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  10. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  11. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  12. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  13. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  14. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1

  15. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  16. Oct 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Glenmark Pharmaceuticals S.A.
  • Ichnos Sciences SA
Data source: Ichnos Sciences SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States, Créteil, France, Denver, United States, Durham, United States, Hackensack, United States, Lille, France, Marseille, France, Nantes, France, Nashville, United States, New York, United States and 8 more location s